California Judge Clears Path for Biogen and Genentech MS Drug Royalty Trial

In a notable development in the pharmaceutical industry, a California federal judge has denied Biogen’s request for summary judgment in its ongoing legal battle with Genentech, a subsidiary of Roche Holding AG. The dispute centers on patent royalties related to sales of multiple sclerosis (MS) drugs. The crux of the matter lies in the contract language, which the judge indicated presents a material dispute that warrants further deliberation in court. This decision means that both parties will proceed to a trial scheduled for June. More details about the case and its implications can be accessed here.